» Authors » Jacob Giehm Mikkelsen

Jacob Giehm Mikkelsen

Explore the profile of Jacob Giehm Mikkelsen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 90
Citations 2057
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Paludan S, Pradeu T, Pichlmair A, Wray K, Mikkelsen J, Olagnier D, et al.
Cell Rep . 2024 Dec; 43(12):115070. PMID: 39675007
Early host defense eliminates many viruses before infections are established while clearing others so they remain subclinical or cause only mild disease. The field of immunology has been shaped by...
2.
Nielsen I, Rovsing A, Janns J, Thomsen E, Ruzo A, Boggild A, et al.
Mol Ther Nucleic Acids . 2024 Sep; 35(4):102318. PMID: 39329149
To fully utilize the potential of CRISPR-Cas9-mediated genome editing, time-restricted and targeted delivery is crucial. By modulating the pseudotype of engineered lentivirus-derived nanoparticles (LVNPs), we demonstrate efficient cell-targeted delivery of...
3.
Janns J, Mikkelsen J
Hum Gene Ther . 2024 Aug; 35(17-18):604-616. PMID: 39150015
The invention of next-generation CRISPR/Cas gene editing tools, like base and prime editing, for correction of gene variants causing disease, has created hope for use in patients leading to wider...
4.
Dai Y, Idorn M, Serrero M, Pan X, Thomsen E, Narita R, et al.
Nature . 2024 Jul; 632(8024):383-389. PMID: 39048823
The brain is highly sensitive to damage caused by infection and inflammation. Herpes simplex virus 1 (HSV-1) is a neurotropic virus and the cause of herpes simplex encephalitis. It is...
5.
Thomsen M, Skouboe M, Mohlenberg M, Zhao J, de Keukeleere K, Heinz J, et al.
J Clin Immunol . 2024 Jan; 44(2):56. PMID: 38277122
Varicella zoster virus (VZV) is a neurotropic alphaherpesvirus exclusively infecting humans, causing two distinct pathologies: varicella (chickenpox) upon primary infection and herpes zoster (shingles) following reactivation. In susceptible individuals, VZV...
6.
Haldrup J, Andersen S, Labial A, Wolff J, Frandsen F, Skov T, et al.
Nucleic Acids Res . 2023 Sep; 51(18):10059-10074. PMID: 37678882
Implementation of therapeutic in vivo gene editing using CRISPR/Cas relies on potent delivery of gene editing tools. Administration of ribonucleoprotein (RNP) complexes consisting of Cas protein and single guide RNA...
7.
Ryo L, Haslund D, Rovsing A, Pihl R, Sanrattana W, de Maat S, et al.
J Allergy Clin Immunol . 2023 Jun; 152(5):1218-1236.e9. PMID: 37301409
Background: Patients with hereditary angioedema experience recurrent, sometimes life-threatening, attacks of edema. It is a rare genetic disorder characterized by genetic and clinical heterogenicity. Most cases are caused by genetic...
8.
Rovsing A, Thomsen E, Nielsen I, Skov T, Luo Y, Dybkaer K, et al.
Br J Haematol . 2023 May; 202(4):825-839. PMID: 37190875
The frontline therapy R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL) has remained unchanged for two decades despite numerous Phase III clinical trials investigating new alternatives. Multiple large studies...
9.
Wolff J, Mikkelsen J
Front Genome Ed . 2023 Mar; 5:1148650. PMID: 36969373
Prime editing of human hematopoietic stem cells has the potential to become a safe and efficient way of treating diseases of the blood directly in patients. By allowing site-targeted gene...
10.
Romer T, Khoder-Agha F, Koed Moller Aasted M, de Haan N, Horn S, Dylander A, et al.
Glycobiology . 2023 Jan; 33(9):700-714. PMID: 36648436
Introduction: In epithelial cancers, truncated O-glycans, such as the Thomson-nouveau antigen (Tn) and its sialylated form (STn), are upregulated on the cell surface and associated with poor prognosis and immunological...